Skip to main content
  • EN
  • FI
  • SV
Login

Main navigation

  • About FinnGen
    • Summary & Goals
      • Goals
      • FinnGen 1-2
      • FinnGen 3 (2023-2027)
    • Consortium
      • Partners
      • Funding
      • Governance
      • Steering Committee Members
      • Scientific Committee Members
      • Teams
      • Collaboration
    • Impact
      • National Impact
      • National Research Network
      • Open Science
      • Research Highlights
    • Why Finland?
      • Biobank Network
      • Legislative Review
      • National Registries
      • Population Genetic History
      • Industry partners
    • Mediabank
  • For Researchers
    • Research Activities
      • Core Analyses
      • Disease Task Forces
      • Expansion Areas
      • Global Initiatives
    • Cohort and Data
      • Register Data
      • Basic Characteristics
      • Clinical Endpoints
      • Genetic Data
      • Laboratory Values
      • Other Phenotype Data
      • Recruitment
      • Other Biological Data
      • Data Available
    • Accessing Data, Results & Tools
      • Access results
      • Computing environment
      • How we collaborate
      • Partner researchers
      • Public data releases
      • Tools
    • Publications
    • Researcher FAQ
  • For Participants
    • Participation
      • Study Participants
      • Biobanks' Role in FinnGen
      • Biobank Contact Information
      • Recall Studies
      • Questions and answers
    • Data Protection and Security
      • Data Protection
      • Data Security
      • Sample & Data Flow
      • Data Protection Statement
    • Significance
      • Videos
  • News
  • EN
  • FI
  • SV

Links

  • PheWeb
  • Risteys
  • Meta-analysis Pheweb (FG-MVP-UKBB)
  • FinnGen handbook
  • Meta-analysis Pheweb (FG-UKBB)
  • Coding variant browser
  • Endpoint Browser
  • FinnGen GITHUB
  • LAVAA volcano plot
  • Multiple Manhattan Plot
  • Variant Cluster Corrector
  • Variant Cluster Call Corrector
Breadcrumb
  1. Home

Assessing the efficacy and safety of angiotensinogen inhibition using human genetics

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:54
  • Read more about Assessing the efficacy and safety of angiotensinogen inhibition using human genetics

Genome-Wide Polygenic Risk Score Identifies Individuals at Elevated Parkinson’s Disease Risk

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:41
  • Read more about Genome-Wide Polygenic Risk Score Identifies Individuals at Elevated Parkinson’s Disease Risk

Efficient and accurate frailty model approach for genome-wide survival association analysis in large-scale biobanks

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:38
  • Read more about Efficient and accurate frailty model approach for genome-wide survival association analysis in large-scale biobanks

Genome-wide screen of otosclerosis in population biobanks: 27 loci and shared associations with skeletal structure

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:33
  • Read more about Genome-wide screen of otosclerosis in population biobanks: 27 loci and shared associations with skeletal structure

Findings and insights from the genetic investigation of age of first reported occurrence for complex disorders in the UK Biobank and FinnGen

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:28
  • Read more about Findings and insights from the genetic investigation of age of first reported occurrence for complex disorders in the UK Biobank and FinnGen

A polygenic risk score for Alzheimer's disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:22
  • Read more about A polygenic risk score for Alzheimer's disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S

Interpreting type 1 diabetes risk with genetics and single-cell epigenomics

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 15:17
  • Read more about Interpreting type 1 diabetes risk with genetics and single-cell epigenomics

Enhanced genetic analysis of type 1 diabetes by selecting variants on both effect size and significance, and by integration with autoimmune thyroid disease

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 14:52
  • Read more about Enhanced genetic analysis of type 1 diabetes by selecting variants on both effect size and significance, and by integration with autoimmune thyroid disease

A genetically-informed study disentangling the relationships between tobacco smoking, cannabis use, alcohol consumption, substance use disorders and respiratory infections, including COVID-19

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 14:44
  • Read more about A genetically-informed study disentangling the relationships between tobacco smoking, cannabis use, alcohol consumption, substance use disorders and respiratory infections, including COVID-19

Atlas of epistasis

Submitted by Frida Mäkelä on Mon, 10/17/2022 - 14:38
  • Read more about Atlas of epistasis

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 395
  • Page 396
  • Page 397
  • Page 398
  • Current page 399
  • Page 400
  • Page 401
  • Page 402
  • Page 403
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Contact us

Contact person
finngen-info@helsinki.fi
Follow us on Bluesky
@finngen.bsky.social

Lead organisations

The University of Helsinki is the organization responsible for the FinnGen research project. The Finnish consortium partners include all Finnish public biobanks and their background organisations, so the project covers the whole of Finland. All partners are listed on this page.

About the website

Accessibility statement